Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)
- · 35d
- Not stated
- Not stated
- Nov 22, 2024
Official announcement on nih_guide+grants_gov · opens the funder's page. Always confirm dates there.
Summary
The purpose of this Notice of Funding Opportunity (NOFO) is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to… […]
Other topics in this solicitation
Computational Approaches to Curation at Scale for Biomedical Research Assets (R01 Clinical Trial Not Allowed)
$250k
Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)
Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)
Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)
Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed)
$100k
Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed)
Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science (RC2 Clinical Trials Optional)
Limited Competition: Mentored Research Career Development Program Award in Clinical and Translational Science Awards (CTSA) Program (K12 Clinical Trial Optional)
The rest of this announcement — free with an account
- The full announcement text, not the first two sentences
- All 3 review criteria reviewers score this against, extracted from this announcement
- Whether you are eligible — career stage, institution type, and the windows that close before the deadline does
- What similar funded projects received, from 219,000 past awards
More from National Institutes of Health
Computational Approaches to Curation at Scale for Biomedical Research Assets (R01 Clinical Trial Not Allowed)
$250k
HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
$350k